藥明巨諾－Ｂ (2126.HK)

1.720 -0.030 (-1.71%) 市場開市。 截至 04:08PM HKT。

藥明巨諾－Ｂ

Building B
5th Floor No. 699 Zhong Ke Road Pudong New District
Shanghai
China
86 21 5078 3699
https://www.jwtherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 398

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Yiping Li M.D.	Co-founder, Executive Chairman of the Board & CEO	6.24M	無	1964
Cao Xiaoping Ph.D.	Senior Vice President of Tech Operations	無	無	無
Dr. Shaun Paul Cordoba Ph.D.	Senior VP & Chief Scientific Officer	無	無	1980
Mr. Raymond J. Hage Jr.	Senior Vice President of Corporate Development	無	無	1968
Mr. Qiong Wu	Senior VP & Chief Commercial Officer	無	無	1974
Mr. Mark J. Gilbert M.D.	Senior Advisor & Acting Chief Medical Officer	無	無	無
Ms. Ka Man Ng A.C.I.S., A.C.S.	Company Secretary	無	無	1978

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People's Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.

公司管治

截至 無 止，藥明巨諾－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。